<DOC>
	<DOCNO>NCT02616315</DOCNO>
	<brief_summary>The purpose study determine effect naltrexone hydrochloride ( HCL ) bupropion hydrochloride extend release combination ( NB ) compare placebo weight loss obese participant post bariatric surgery .</brief_summary>
	<brief_title>Efficacy Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo Treatment Weight Regain Participants Post Bariatric Surgery</brief_title>
	<detailed_description>The drug test study call naltrexone hydrochloride/bupropion hydrochloride ( NB ) . NB test determine effect weight loss obese participant post bariatric surgery . The study enroll approximately 60 participant . Participants randomly assign one two treatment groups—which remain undisclosed participant study doctor study ( unless urgent medical need ) : - Naltrexone HCl 32 mg/bupropion HCl 360 mg extended-release tablet - Placebo ( dummy inactive pill ) - tablet look like study drug active ingredient All participant start 1 tablet day increase dose 1 tablet per week 4 week reach optimal dose . This multi-center trial conduct United States . The overall time participate study 59 week maximum . Participants make multiple visit clinic , plus final visit 4 week last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Is female male age 18 65 year , inclusive . 4 . Is least 2 year post RouxenY Gastric Bypass ( RYGB ) procedure treatment severe obesity prior screen . 5 . Has achieve initial weight loss ≥20 % preoperative body weight , regain ≥10 % total weight lose . 6 . Has body mass index ( BMI ) ( weight [ kg ] / [ height { } ] ^2 ) ≥30 kg/m^2 . 7 . A female participant childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception signing inform consent throughout duration study 12 week last dose study drug . 8 . Is able speak read English . 1 . Has obesity know endocrine origin ( eg , untreated hypothyroidism , Cushing 's syndrome ) genetic origin . 2 . Is currently use bupropion naltrexonecontaining product history hypersensitivity allergies naltrexone bupropion . 3 . Has history cancer remission &lt; 5 year prior screen . A history basal cell carcinoma Stage 1 squamous cell carcinoma skin allow . 4 . Has history Type 1 current type 2 diabetes mellitus ( T2DM ) diagnosis . 5 . Has myocardial infarction within 6 month prior screen . 6 . Has history Class III IV congestive heart failure , per New York Heart Association functional classification . 7 . Has history angina pectoris Grade III IV , per Canadian Cardiovascular Society grade scheme . 8 . Has clinical history stroke , include ischemic hemorrhagic stroke . 9 . Has history ( within last 20 year ) seizures , cranial trauma , active bulimia , anorexia nervosa , condition predispose participant seizure . 10 . Has , judgment investigator , clinically significant electrocardiogram ( ECG ) , laboratory , hematology , physical examination , medical history , urinalysis find prohibit participation study . 11 . Has uncontrolled hypertension define blood pressure ( BP ) ≥145/95 mm Hg screening . BP measure 2 separate occasion approximate 30minute interval measurement screen visit . 12 . Has thyrotropin ( thyroid stimulate hormone TSH ) value outside normal range screen visit ; unless normal triiodothyronine ( T3 ) value . 13 . Had initiation alteration dose antihypertensive lipidlowering agent within 4 week prior screen . 14 . Used prescribed overthecounter drug intend weight loss , participate weight loss program standard care post bariatric population , within 3 month prior randomization . 15 . Has prior plan surgical device intervention obesity except require RYGB Surgery . 16 . Has history current diagnosis angleclosure glaucoma . 17 . Is experience post bariatric dump syndrome may impact conduct outcome study determine investigator . 18 . Has moderate severe renal impairment ( endstage renal disease ) define estimate glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73m^2 , use Chronic Kidney Disease Epidemiology Collaboration equation ( CKDEPI ) . 19 . Has clinical history hepatic impairment current documented aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3 time upper limit normal ( ULN ) screen visit . 20 . Has glycosylated hemoglobin ( HbA1c ) ≥6.5 % Screening Visit . 21 . Has current know infection human immunodeficiency virus ( HIV ) hepatitis ( documentation detectable virus require participant past infection hepatitis B C ) . 22 . Is undergo abrupt discontinuation alcohol , benzodiazepine , barbiturate , antiepileptic drug . 23 . Is chronic user positive screen opioids . 24 . Has hemoglobin ≤10 g/100 mL screen visit . 25 . Has history serious psychiatric illness : A Patient Health Questionnaire ( PHQ ) 9 score ≥10 screen visit . Bipolar disorder . Schizophrenia . Severe personality disorder ( eg , borderline antisocial ) . Major depressive disorder . Recent ( previous 6 month ) suicide attempt . Other psychosis . 26 . If female , participant pregnant try become pregnant , currently breastfeed , childbearing potential ( include perimenopausal woman menstrual period within 1 year ) willing practice birth control signing inform consent throughout duration study 12 week last dose study drug . 27 . Has receive investigational compound within 30 day prior first dose study medication . 28 . Has receive Contrave previous clinical study therapeutic agent . 29 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 30 . Is required take exclude medication . 31 . Participant enrol interventional study time Screening study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>